microdosing semaglutide for perimenopause GLP-1 Women | Personalized Dosing Microdosing GLP-1 for Perimenopause: Why

Because both estrogen and GLP-1 are known to act on receptors in the hypothalamus, research suggests that both may work through converging signaling pathways to regulate lipid and glucose metabolism

When you eat, your gut releases natural GLP-1

Melanie Cree, director of the University of Colorados PCOS multidisciplinary clinic and pediatric endocrinologist at Childrens Hospital Colorado, is the main investigator on a clinical trial testing semaglutide in 80 obese girls and women with PCOS aged 12 to 35

Lilly continues to study the long-term effects of these medicines and works closely with healthcare professionals and people living with obesity to support their safe and appropriate use." What Happens Next The study's authors recommend that guidelines be reviewed so that patients receiving the medications are made aware of the likelihood of rapid weight regain unless the medication is sustained long-term

COPYRIGHT 2024-2025 THE MEDSPA SOCIETY, LLC